Treatment of Travelers' Diarrhea: Randomized Trial Comparing Rifaximin, Rifaximin Plus Loperamide, and Loperamide Alone. [Clin Gastroenterol Hepatol] Journal article | | Title | Treatment of Travelers' Diarrhea: Randomized Trial Comparing Rifaximin, Rifaximin Plus Loperamide, and Loperamide Alone. | | Author(s) | Dupont HL, Jiang ZD, Belkind-Gerson J, Okhuysen PC, Ericsson CD, Ke S, Huang DB, Dupont MW, Adachi JA, De La Cabada FJ, Taylor DN, Jaini S, Martinez Sandoval F | | Institution | Center for Infectious Diseases, University of Texas School of Public Health, Houston, Texas; Department of Internal Medicine, University of Texas School of Medicine, Houston, Texas; Division of Molecular Imaging, Baylor College of Medicine, Houston, Texas; St. Luke's Episcopal Hospital, Houston, Texas. | | Source | Clin Gastroenterol Hepatol 2007 Mar 21. | | Abstract | BACKGROUND & AIMS: Antimotility agents provide rapid temporary relief of acute diarrhea, whereas antibiotics slowly cure the illness. Thus, the combination of an antimotility agent and an antibiotic may provide greater therapeutic benefit than either drug alone. This study evaluated the efficacy and safety of rifaximin-loperamide in the treatment of travelers' diarrhea.
METHODS: Consenting adults with acute diarrhea (>/=3 unformed stools in 24 hours with >/=1 symptom of enteric infection) were randomized to receive rifaximin 200 mg 3 times daily for 3 days; loperamide 4 mg initially followed by 2 mg after each unformed stool; or a combination of both drugs using the same dosing regimen. The primary end point was the median time from beginning therapy until passing the last unformed stool.
RESULTS: A total of 310 patients completed treatment with rifaximin (n = 102), loperamide (n = 104), or rifaximin-loperamide combination therapy (n = 104). The groups showed demographic similarity. Rifaximin and rifaximin-loperamide significantly reduced the median time until passage of the last unformed stool (32.5 +/- 4.14 h and 27.3 +/- 4.13 h, respectively) vs loperamide (69 +/- 4.11 h; P = .0019). The mean number of unformed stools passed during illness was lower with rifaximin-loperamide (3.99 +/- 4.28) compared with rifaximin (6.23 +/- 6.90; P = .004) or loperamide alone (6.72 +/- 6.93; P = .002). All treatments were well tolerated with a low incidence of adverse events.
CONCLUSIONS: Rifaximin-loperamide therapy provided rapid symptomatic improvement and greater overall wellness compared with either agent alone. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 17382603 |
|
|
| |
Advertise on this site.
| | |
|
